Feed IONS
IO

Ionis Pharmaceuticals

IONS · NASDAQ

$47.25 -7.64% (-$3.91)
1M -12.26%
Market Cap $8.55B
P/E Ratio -
Div. Yield -
ROE 110.84%
Piotroski F-Score Weak
2/9
Valuation
56 /100
Fair
EV/EBITDA 2.45x
P/S 9.78x
P/B 19.44x
Growth
75 /100
Growing
Rev. growth 17.14%
Book val. growth 5.13%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 98.16%
Net margin 64.64%
Op. margin 68.09%
Quality
4 /100
Poor
ROIC 20.37%
ROE 110.84%
ROA 18.86%
Debt
50 /100
Moderate
Debt/Equity 5.50x
Current ratio 7.88x
Int. coverage -5.61x
Stability
47 /100
Moderate
Beta 0.42x
Rev. volatility 25.67%
EPS volatility 29.09%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about IONS
Online

About the company

Ionis Pharmaceuticals, Inc. is an American biotechnology company specializing in the development of RNA-targeted therapies for the treatment of various severe diseases. The company utilizes advanced antisense oligonucleotide (ASO) technology, which allows for targeted modification of RNA and regulation of gene expression, useful in treating conditions such as amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, and various genetic disorders. Ionis Pharmaceuticals is a leader in innovative treatment approaches, offering new possibilities for patients with previously untreatable diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Brett Monia

Employees

1,480

Headquarters

Carlsbad

Upcoming events

04 NOV

Earnings

Upcoming earnings report

50d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.